NCT02413203View on ClinicalTrials.gov

Lipidomics Screening of Celecoxib in ex Vivo Human Whole Blood Assay - Part B

NACompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions
Healthy
Interventions
DRUG

Celecoxib

Blood and urine collections before and 3 hours after celecoxib administration.

DRUG

Placebo

Blood and urine collections before and 3 hours after placebo administration.

Trial Locations (1)

19104

The Clinical Translational Research Center (CTRC) at the Hospital of the University of Pennsylvania, Philadelphia

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

University of Pennsylvania

OTHER

NCT02413203 - Lipidomics Screening of Celecoxib in ex Vivo Human Whole Blood Assay - Part B | Biotech Hunter | Biotech Hunter